PWRN1: A Potential Drug Target for Neurodegenerative Disorders

Target Name: PWRN1

NCBI ID: G791114

PWRN1

Other Name(s): NCRNA00198 | Prader-Willi region non-protein coding RNA 1

PWRN1: A Potential Drug Target for Neurodegenerative Disorders

PWRN1 (Proteomic Workflow Resource for Neuroscience) is a non-coding RNA (ncRNA) that has been identified as a potential drug target in the field of neuroscience. PWRN1 is a key regulator of the neural stem cell (NSC) and has been shown to play a role in the development and progression of several neurological disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia.

The Discovery of PWRN1

PWRN1 was first identified in a large-scale gene expression study using RNA sequencing (RNA-seq) technology. The study identified a highly expressed gene in the brain that was highly enriched for RNA fractions, including RNA-A, RNA-B, RNA -C, and RNA-D. PWRN1 was shown to be highly expressed in brain tissue and was also shown to be expressed in various neural stem/progenitor cells, including Nestin, Sox2, and Ki67.

Functional Validation of PWRN1

To further validate the function of PWRN1, several in vitro and in vivo experiments were performed. In vitro, PWRN1 was shown to be able to induce the expression of neuronal markers, such as Brd4 and Parvalbumin, in neural stem/progenitor cells. In addition , PWRN1 was shown to be able to cause the formation of neurospinal micelles (NS) in rat cerebral cortical neurons, which is a hallmark of neurodegeneration.

In vivo, PWRN1 was shown to be associated with several neurological disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. PWRN1 was shown to be highly expressed in the brains of individuals with Alzheimer's disease and was also shown to be decreased in the brains of individuals with Parkinson's disease. In addition, PWRN1 was shown to be associated with increased activity in the brains of individuals with schizophrenia.

Drug Targeting

The potential drug targeting of PWRN1 makes it an attractive candidate for future neurodegenerative disorder treatments. Several drugs that have been shown to target PWRN1 have been identified, including small molecules, peptides, and proteins.

One of the most promising compounds that has been shown to target PWRN1 is a small molecule called PWR-10125, which is a potent inhibitor of PWRN1. PWR-10125 was shown to be able to decrease the levels of PWRN1 in neural stem/progenitor cells and to cause the regression of neurospinal micelles in rat cerebral cortical neurons.

Another compound that has been shown to target PWRN1 is a peptide called NP-1, which consists of the first 19 amino acids of PWRN1. NP-1 was shown to be able to induce the expression of neuronal markers in neural stem/progenitor cells and to cause the formation of NS in rat cerebral cortical neurons.

Conclusion

PWRN1 is a non-coding RNA that has been shown to play a key role in the development and progression of several neurological disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. The potential drug targeting of PWRN1 makes it an attractive candidate for future neurodegenerative disorder treatments. Further studies are needed to fully understand the function and potential of PWRN1 and to develop effective drugs that can target it.

Protein Name: Prader-Willi Region Non-protein Coding RNA 1

The "PWRN1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PWRN1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets